By vgreene, 28 October, 2021 Study considerations randomized but open label delayed tx initiation from sx onset viral kinetics showed possible lack of antiviral effect LPV r exposure at normal doses lower vs concentrations needed for anti SARS CoV 2 activity
By vgreene, 28 October, 2021 No difference in median time to clinical improvement LPV r 16 days vs SOC 16 days or 28 day mortality LPV r 19 vs SOC 25 rate of detectable viral load similar between groups at all sampling timepoints similar rates of ADRs LPV r 48 vs SOC 50 14 of LPV r p
By vgreene, 28 October, 2021 Open label RCT 199 hospitalized pts mean age 58y w confirmed SARS CoV 2 and O2 sat 94 on RA randomized 1 1 to LPV r 400 mg 100 mg bid x14 days plus SOC or SOC alone 13 days median time btwn sx onset and randomization SOC group had higher rates of vasopres
By vgreene, 28 October, 2021 Study considerations randomized but open label delayed tx initiation from sx onset viral kinetics showed possible lack of antiviral effect LPV r exposure at normal doses lower vs concentrations needed for anti SARS CoV 2 activity
By vgreene, 28 October, 2021 A Trial of Lopinavir Ritonavir in Adults Hospitalized With Severe Covid 19
By vgreene, 28 October, 2021 Drugs under investigation lopinavir ritonavir darunavir w ritonavir darunavir cobicistat
By vgreene, 28 October, 2021 Proposed mechanism interferes w maturation of viral particles by inhibiting protease enzymes
